Melinda Griffith - Aug 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Director
Signature
/s/ Melinda Griffith
Stock symbol
OCX
Transactions as of
Aug 15, 2022
Transactions value $
$10,000
Form type
4
Date filed
8/17/2022, 08:18 PM
Previous filing
Jul 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Award $0 +10K +100% $0.00 20K Aug 15, 2022 Direct F1
transaction OCX Common Stock, no par value Purchase $10K +10K +50% $1.00 30K Aug 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +45K $0.00 45K Aug 15, 2022 Common Stock 45K $0.97 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2 Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.